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Abstract: Paget’s disease of bone (PDB) is a progressive monostotic or polyostotic metabolic 
bone disease characterized by focal abnormal bone remodeling, with increased bone resorption 
and excessive, disorganized, new bone formation. PDB rarely occurs before middle age, and 
it is the second most frequent metabolic bone disorder after osteoporosis, affecting up to 3% 
of adults over 55 years of age. One of the most striking and intriguing clinical features is the 
focal nature of the disorder, in that once the disease is established within a bone, there is only 
local spread within that bone and no systemic dissemination. Despite many years of intense 
research, the etiology of PDB has still to be conclusively determined. Based on a detailed 
review of genetic and viral factors incriminated in PDB, we propose a unifying hypothesis 
from which we can suggest emerging strategies and therapies. PDB results in weakened bone 
strength and abnormal bone architecture, leading to pain, deformity or, depending on the 
bone involved, fracture in the affected bone. The diagnostic assessment includes serum total 
alkaline phosphatase, total body bone scintigraphy, skull and enlarged view pelvis x-rays, and 
if needed, additional x-rays. The ideal therapeutic option would eliminate bone pain, normal-
ize serum total alkaline phosphatase with prolonged remission, heal radiographic osteolytic 
lesions, restore normal lamellar bone, and prevent recurrence and complications. With the 
development of increasingly potent bisphosphonates, culminating in the introduction of a 
single intravenous infusion of zoledronic acid 5 mg, these goals of treatment are close to 
being achieved, together with long-term remission in almost all patients. Based on the recent 
pathophysiological   findings, emerging strategies and therapies are reviewed: ie, pulse treatment 
with zoledronic acid; denosumab, a fully human monoclonal antibody directed against RANK 
ligand; tocilizumab, an interleukin-6 receptor inhibitor; odanacatib, a cathepsin K inhibitor; 
and proteasome and Dickkopf-1 inhibitors.
Keywords: Paget’s disease of bone, bisphosphonates, sequestosome 1, p62, autophagy, 
  pathogenesis, interleukin-6
Introduction
Paget’s disease of bone (PDB) is a progressive monostotic or polyostotic metabolic 
bone disease characterized by focal abnormal bone remodeling, with increased bone 
resorption and excessive, disorganized new bone formation.1 The disease is driven 
primarily by increased osteoclast activity, but intrinsic defects in other cell types in 
the bone microenvironment may contribute to disease onset and severity.2 One of the 
most striking and intriguing clinical features is the focal nature of the disorder, in 
that once the disease is established within a bone, there is only local spread within 
that bone and no systemic dissemination.3 Further supporting this focal nature, is 
the clinical observation of PDB transfer from one part of the skeleton to another as Drug Design, Development and Therapy 2011:5 submit your manuscript | www.dovepress.com
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a result of autologous bone grafting after three years’ latency.4 
While PDB is classically considered to be a focal disease, 
there is some evidence to suggest that patients have a mild 
generalized increase in bone turnover as measured by histo-
morphometry in nonpagetic sites.5
PDB affects both men and women, with a slight predomi-
nance in men.1 PDB rarely occurs before middle age and its 
prevalence increases steadily with age. It is the second most 
frequent metabolic bone disorder after osteoporosis, affecting 
up to 3% of adults over 55 years of age,6 with an unchanged 
prevalence (2.5%) over the last 1000 years,7,8 although it 
appears to be declining over the last 50 years,9 which is con-
sistent with a major contribution of environmental triggers for 
PDB. PDB results in weakened bone strength and abnormal 
bone architecture, in which the collagen fibers assume a 
haphazard irregular mosaic pattern (woven bone) instead of 
the parallel symmetry observed in normal   (lamellar) bone. 
PDB is often asymptomatic, but patients can present with 
pain, deformity or, depending on the bone involved, fracture 
in the affected bone.10   Approximately 30%–50% of PDB 
patients experience disabilities due to bone pain, osteoar-
thritis secondary to deformities adjacent to weight-bearing 
joints, fractures, or nerve root compression.11,12 Malignant 
transformation to osteosarcoma occurs in about 0.3% of 
patients.11
Despite many years of intense research, the etiology of 
PDB has still to be conclusively determined. A variety of 
evidence has implicated members of the Paramyxovirus 
family as causative agents;13–18 UK researchers have previ-
ously shown molecular evidence of canine distemper virus 
in pagetic bone biopsies,15–18 whereas groups in the US 
have predominantly identified measles virus.19,20 Although 
controversial, these data may suggest a slow viral infection 
in pagetic bone.21,22 Further supporting this viral hypothesis 
are the frequent associations between the development of 
PDB and contact with domesticated animals or residency in 
rural areas.23–25 The high prevalence of PDB in Lancashire 
  (England) and in New Zealand may be related to both envi-
ronmental and genetic factors. The declining prevalence 
and severity of PDB in the British population also suggests 
that PDB is at least somewhat regulated by environmental 
factors,26,27 although it may be partially due to the influx of 
migrants from low prevalence regions such as the Indian 
subcontinent and southeast Asia.28 In contrast, the rural 
region of Campania (Italy) was recently reported to be a 
high prevalence area for PDB with an increased clinical 
severity.29,30
Diagnosis
PDB may present with obvious signs or symptoms or it 
may be an incidental finding during the investigation of 
other conditions.10 In a recent study, PDB appears to be less 
severe, with 34% having a monostotic lesion, and an overall 
average of 5.5 lesions per patient.31 The diagnosis of PDB is 
primarily radiological and confirmed with plain radiology of 
at least one skeletal site.10 The radiological features include 
initial osteolytic changes (V-shaped lesions in long bones 
and osteoporosis circumscripta in the skull), followed by 
sclerotic changes, bone enlargement, and cortical   thickening. 
Plain radiographs are also valuable in the diagnosis of 
secondary complications of PDB, eg, arthritis or fracture. 
Total body bone scintigraphy is more sensitive than x-rays 
and, it is recommended (where available) for patients with 
asymptomatic PDB and for patients with symptomatic PDB 
to assess the extent of skeletal involvement.32 In contrast with 
focal assessment of disease by scintigraphy and   radiography, 
biochemical markers of disease activity provide an inte-
grated index, if not of the focal activity of the underlying 
disorder, then of its extent.33,34 Measurement of serum total 
alkaline phosphatase is still the most frequently used and 
most useful biochemical marker for clinical management of 
PDB.35 Serum bone alkaline phosphatase and procollagen 
type 1 N-terminal propeptide, as well as urinary N-terminal 
telopeptide of type 1 collagen and α-C-terminal telopeptide 
of type 1 collagen have been demonstrated to be similar36 or 
slightly superior37,38 to serum total alkaline phosphatase in 
assessing disease activity and response to therapy in small 
cohorts of patients. However, monostotic PDB may be asso-
ciated with levels of serum total alkaline phosphatase within 
the reference range, introducing difficulties both in diagno-
sis and follow-up management of patients.39 PDB patients 
with serum total alkaline phosphatase within the reference 
range may be discriminated from normal controls by an 
increased bone alkaline phosphatase isoform B2   measured 
by high-pressure liquid chromatography.40 In contrast, serum 
osteocalcin is not a sensitive marker in PDB, being often in 
the normal range.41,42
In summary, the assessment of PDB includes serum total 
alkaline phosphatase, total body bone scintigraphy, skull and 
enlarged view pelvis x-rays (includes pelvis, 1/3 proximal 
femurs and L3 to L5 vertebrae), and if needed, additional 
x-rays. This clinical investigation is associated with very 
high diagnostic sensitivities for PDB, ie, 85%–91% for skull 
and enlarged view pelvis x-rays43 and 97%–98% for bone 
scintigraphy.44Drug Design, Development and Therapy 2011:5 submit your manuscript | www.dovepress.com
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Pathogenesis
Genetic factors
Genetic factors play an important role in PDB.45 One-third 
of patients with PDB have a familial form transmitted in an 
autosomal dominant pattern of inheritance with incomplete 
penetrance.46–48 Genetic heterogeneity has been demonstrated 
in familial forms of PDB, which have been linked to several 
chromosomal regions.49 A linkage between the 6p21.3 locus 
(PDB1) and PDB has been suggested, but not confirmed.50 
Four PDB families were linked to markers in the 18q22.1 
locus (PDB2), a locus also involved in familial expansive 
osteolysis, a rare bone disease caused by a mutation in the 
tumor necrosis factor receptor superfamily, member 11a, 
NFKB activator (RANK, TNFRSF11A) gene.51,52 However, 
RANK gene mutations are not a common cause of classical 
late-onset PDB,53,54 although a genetic association to this 
gene was recently suggested in PDB patients.55 The   5q35-qter 
locus (PDB3) was identified by our research group in a 
genome-wide scan of three large French-Canadian families,48 
and replicated in British families.56 Taking advantage of the 
influence of genetic drift and a strong founder effect of the 
French-Canadian population, we reported in this population 
the first and still most common germline mutation, P392L, 
within the SQSTM1 gene,57 and this was later confirmed in 
the British population.58 The 5q31 locus (PDB4) was also 
linked to PDB in two French-Canadian families.48 A genome-
wide scan in 62 British families suggested the linkage of 
PDB with two other loci, 2q36 (PDB5) and 10p13 (PDB6).56 
Recently, data from this genome-wide scan were reanalyzed 
and confirmed a linkage to the 10p13 locus, but not to the 
2q36 locus.59 The 18q23 locus (PDB7) was suggested in an 
Australian family,60 but this locus is more likely to contain a 
modifier gene rather than a causal gene because a SQSTM1 
mutation (L394X) was also found in this pedigree.61 Although 
no linkage of the osteoprotegerin (OPG, TNFRSF11B) locus 
(8q24) was suggested with PDB, a British study reported 
a female sex-restricted association of this gene with PDB.62,63 
Mutations of the valosin-containing protein (VCP) gene, 
located at 9p13-p12, were reported in rare families charac-
terized by an autosomal dominant disorder associating PDB 
with frontotemporal dementia or inclusion body myopathy.64 
However, no mutations were found in pagetic patients in 
the absence of myopathy or dementia, suggesting that the 
VCP gene was not a common causal gene of PDB.65 Finally, 
a recently published genome-wide association study in PDB 
patients, mostly of British descent, identified a significant 
association between PDB and six common variants, located 
at the 1p13 (CSF1 gene) and 10p13 (OPTN gene) loci, 
and, as previously mentioned, at the 18q21 (RANK gene) 
locus.55 These genetic associations have been strongly 
replicated in Belgian and Dutch populations, as well as the 
association of the dendritic cell-specific transmembrane 
protein   (DC-STAMP , TM7SF4) gene, encoding for a protein 
involved in cell–cell fusion of osteoclasts.66 Among the seven 
reported loci, the 5q35qter (PDB3) locus is the only one for 
which a gene has been identified, namely the sequestosome 1 
(SQSTM1) gene that encodes the SQSTM1/p62 protein.57 
More than 20 missense or truncating germline mutations 
of this gene have now been reported, although the P392L 
mutation is the most frequent.67,68 In the French-Canadian 
population, the P392L recurrent mutation was involved in 
46% of familial forms and 16% of unrelated cases of PDB.57 
Sequencing of the SQSTM1 gene in unrelated French PDB 
patients allowed the identification of two novel mutations, 
A381V and L413F, and for the first time, the presence of 
double mutations of SQSTM1 was reported in PDB.69 In the 
American population, 10% of unrelated PDB patients living 
in the New York City area carried a SQSTM1 mutation, most 
frequently the P392L mutation, but also the novel S349T, 
A390V, and L417Q mutations.70 Almost all of the SQSTM1 
mutations are recurrent, and reported in different Caucasian 
populations on average in 40% of familial forms of PDB and 
8% of unrelated patients.61,67,69,71
NF-κB signaling pathway
Interestingly, all of the reported SQSTM1 germline mutations 
result in either missense or truncating mutations67 enhanc-
ing the NF-κB signaling pathway. They are clustered either 
within or near the C-terminal region of the SQSTM1/p62 
protein that embodies the ubiquitin-associated domain. 
This suggests that an alteration of ubiquitin-chain bind-
ing by SQSTM1/p62 is important in the development of 
PDB,72,73 resulting in an aberrant RANK-NF-κB signaling 
pathway.74 In osteoclasts, SQSTM1/p62 has been described 
as a scaffolding protein that interacts with TRAF6 follow-
ing activation by the RANK ligand (Figure 1).75 Activation 
of this complex results mainly in the activation of NF-κB 
and NFATc1 transcription factors. The overexpression of 
SQSTM1/p62 in osteoclasts from PDB patients induces 
major shifts in the pathways activated by the RANK ligand 
and upregulates osteoclast activity. The P392L mutation may 
contribute to the overactive state of osteoclasts in PDB,76 and 
could potentially explain the generalized increase in bone 
turnover observed in nonpagetic bone sites.5Drug Design, Development and Therapy 2011:5 submit your manuscript | www.dovepress.com
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Figure 1 Most relevant pathways for the identification of potential novel therapeutic targets in Paget’s disease of bone.
Ubiquitin-proteasome system, autophagy, 
and apoptosis
The ubiquitin-proteasome system is involved in the degrada-
tion of short-lived, damaged, or misfolded proteins. Target-
to-be-degraded proteins are first tagged with ubiquitin then 
digested by the proteasome.77,78 This system is important 
for protein degradation and controls various cell functions, 
including mitosis, signal transduction, gene transcription, 
immune response, and apoptosis.
Autophagy is another protein degradation system, and 
includes macroautophagy, microautophagy, and chaperon-
mediated autophagy.79,80 Macroautophagy (hereafter termed 
autophagy) involves the engulfing of a portion of cytoplasm 
by a double-membrane structure, the autophagosome. 
The autophagosome fuses with the lysosome, becoming 
the autolysosome, which undergoes autodigestion.80,81 
Autophagy maintains cellular homeostasis and participates in 
processes including differentiation, remodeling, growth con-
trol, cell defense, and adaptation to adverse environments,82 
and is involved in eliminating abnormal proteins.83 Loss of 
autophagy in mice induces inclusion formation in neurons 
and hepatocytes.84,85
Ubiquitination, through binding of the ubiquitin-
associated domain of the p62 protein (encoded by the 
SQSTM1 gene) to LC3 protein, mediates protein degradation 
by autophagy and also results in the delivery of p62 itself to 
autophagosomes for lysosomal degradation.86–88 So far, only 
one PDB-associated germline missense mutation (D335E) 
has been shown to affect the LC3-binding region.89 In PDB, 
autophagy appears to be defective, with impaired p62 clear-
ance that leads to increased levels of p62 regardless of the 
SQSTM1 mutation status.69,76 p62 not only functions as an 
adaptor protein that targets substrates to the autophagosome, 
but also as a scaffold protein interacting with TRAF6 and 
caspase 8, promoting polyubiquitination of TRAF6 and 
activation of NF-κB signaling,90,91 as well as the aggrega-
tion of cullin-3 modified caspase 8, required for apoptosis, 
within p62-dependent foci92 which leads to increases in 
osteoclast survival.76 These increases in osteoclast survival 
can be induced by artificial overexpression of p62 and appear 
to be independent of SQSTM1 mutations because they are 
observed with wild-type and PDB-mutant p62.76 Finally, it 
is interesting to note that osteoclasts from healthy carriers of 
germline SQSTM1/p62P392L mutation show an intermediate Drug Design, Development and Therapy 2011:5 submit your manuscript | www.dovepress.com
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rate of apoptosis between affected individuals and healthy 
controls.76 Exploring the precise nature of the potential link 
between autophagy and PDB has been judiciously proposed 
as a priority area because autophagy represents a cellular 
pathway that can be relatively easily manipulated in vivo 
by pharmacological agents.93
viral factors
Canine distemper virus
Canine distemper virus can infect and replicate in human 
osteoclast precursors, raising possible zoonotic implications 
for canine distemper virus. Canine distemper virus transiently 
induces osteoclastogenesis in human osteoclast precursor 
cultures via NF-κB and SQSTM1/p62 activation.94 A variety 
of other proteins have been shown to be upregulated in PDB, 
notably Bcl-2,95 leading to an enhanced lifespan of pagetic 
osteoclasts. Hence, it is possible that the viral effects on 
  ubiquitin and SQSTM1/p62 are only transient, but that the 
effects on other proteins, such as Bcl-2, lead to an enhanced 
lifespan of the enlarged osteoclast, with the subsequent 
recruitment of further precursor cells, thus increasing the 
size and bone resorbing capacity further.
Measles virus nucleocapsid protein
Osteoclasts in PDB are increased in number and size and 
express a “pagetic phenotype” that distinguishes them from 
normal osteoclasts. They contain up to 100 nuclei/osteoclast 
compared with 3–10 nuclei in normal osteoclasts, their 
precursors are hyperresponsive to the RANK ligand, tumor 
necrosis factor alpha, and 1,25(OH)2 vitamin D3,
96–98 and 
form osteoclast at physiologic concentrations of 1,25(OH)2 
  vitamin D3 (10−11 M) rather than the pharmacologic 
1,25(OH)2   vitamin D3 concentrations (10−8 M) required for 
normal osteoclast formation. The 1,25(OH)2 vitamin D3 
hyperresponsivity results from elevated levels of a novel 
vitamin D receptor coactivator, TAF12 (formerly TAFII-17) 
in osteoclasts.97 Furthermore, osteoclasts in PDB secrete 
high levels of interleukin (IL)-6, which are detectable in 
marrow plasma and peripheral blood from patients with 
Paget’s disease.99
Both measles virus nucleocapsid (MVNP) and the 
SQSTM1/p62P392L mutation have been implicated in the 
pathogenesis of PDB, but their relative contributions are not 
yet clearly defined. We recently reported that osteoclast 
from approximately 70% of PDB patients express MVNP, 
and that normal osteoclast precursors expressing MVNP 
formed osteoclasts that express the “pagetic phenotype”.100,101 
  Furthermore, 30% of transgenic mice with targeted 
  expression of MVNP to osteoclasts developed osteoclast 
and bone lesions characteristic of PDB.102
At least 21 genetic mutations of the SQSTM1/p62 gene 
are linked to PDB, with p62P392L mutation being the most 
frequent.57,67,103 However, the role of p62P392L in PDB is 
unclear because normal osteoclast precursors express-
ing p62P392L are hyperresponsive to the RANK ligand but 
not to 1,25(OH)2D3, do not express high levels of IL-6 or 
TAF12, or form bone lesions or osteoclasts characteristic 
of PDB.104,105
Therefore, to assess the roles of MVNP and p62P392L in 
PDB, marrow from clinically involved and uninvolved bones 
of PDB patients with p62P392L and normals was tested for 
MVNP, and the effects of antisense MVNP on the osteoclast 
formed were determined.101 To delineate the mechanism(s) 
responsible for the abnormal osteoclast activity and bone 
formation seen with coexpression of MVNP and p62P392L, 
p62P394L knockin mice (the mouse equivalent of p62P392L) 
were bred to transgenic mice expressing MVNP in osteoclasts 
producing the p62P394L knockin/MVNP mice. These mice 
developed more pagetic osteoclast and pagetic bone lesions 
than transgenic mice expressing MVNP in osteoclasts.101 
The p62P392L gene increased RANK ligand sensitivity of 
osteoclast precursors while MVNP was responsible for 
osteoclast hypermultinucleation, increased TAF-12 expres-
sion, and IL-6 production through enhanced p38MAPK 
signaling induced by 1,25(OH)2D3.101 Furthermore, when 
transgenic mice expressing MVNP in osteoclasts were bred 
to IL-6 knockout mice, pagetic osteoclast formation no 
longer occurred.101
In conclusion, studies in mice have demonstrated that the 
p62P392L mutation leads to some of the phenotypic character-
istics of PDB, but this single mutation is seemingly unable 
to result in the whole PDB phenotype. This mutation may 
predispose to PDB by increasing the sensitivity of osteo-
clastic precursors to osteoclastogenic cytokines104 and/or the 
  osteoclastogenic potential of the bone microenvironment,105 
probably in association with other biological mechanisms, 
such as the presence of MVNP, which is responsible 
for osteoclast hypermultinucleation, increased TAF-12 
  expression, and IL-6 production.101,106
SQSTM1/p62, selective autophagy,  
and measles virus persistence
A unifying hypothesis for SQSTM1/p62, selective autophagy, 
and measles virus persistence is shown in Figure 2. It has 
been recently suggested that successful clearance of viral 
proteins through p62-mediated selective autophagy may Drug Design, Development and Therapy 2011:5 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
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represent an integral component of the normal host antiviral 
defense response.79 Virus-induced autophagy usually requires 
viral replication80 and is then followed by viral persistence. 
The measles virus is a monotypic virus existing as a single 
serotype and is among the most infectious viruses.89 Measles 
virus infections predominantly occur in children, and infec-
tion or vaccination with any one strain appears to provide 
life-long protection from the disease.89 It would be difficult 
to accept life-long persistence of measles virus RNA or 
protein in the absence of viral replication and low level gene 
expression.86 Indeed, intracellular nonreplicating MVNP 
are inactivated within three days.88 Osteoclasts have a short 
lifespan (2–3 weeks) and are not self-renewing cells, but 
are rather formed by fusion of postmitotic precursors of the 
monocyte-  macrophage lineage.90 Immature multipotential 
hematopoietic progenitors that give rise to granulocytes, 
erythrocytes, macrophages, and platelets, also express MVNP 
transcripts, while nonhematopoietic stromal cells do not.87 
These cells could easily be the reservoir for measles virus 
  persistence in PDB, although direct evidence is lacking. 
  Toll-like receptors 2 and 4 have been shown to increase 
susceptibility to measles virus infection,91 suggesting a 
  predisposing role of innate immunity.
We can then speculate that measles virus persistence 
could explain the latency between measles virus infec-
tion in childhood and PDB development in middle age.86 
Measles virus persistence would also explain the presence 
of MVNP in lifelong immature multipotential hematopoietic 
progenitors,87 later differentiating into osteoclasts, and would 
be responsible for osteoclast hypermultinucleation, increased 
TAF-12 expression, 1,25(OH)2 vitamin D3 responsivity, 
and IL-6 production.101,106 Defective p62-mediated selective 
autophagy of MVNP, by germline SQSTM1/p62 mutation 
or other causes, would lead to accumulation of p62 itself as 
well as MVNP-p62 aggregates in osteoclasts and antigen-
presenting cells, reducing their clearance by the proteasome.79 
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Figure 2 Pathogenesis of Paget’s disease of bone: viral and genetic interactions, unifying hypothesis. Schematic models of cytoplasmic autophagy in A) normal hematopoietic 
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Mutant p62P392L,76 or any other SQSTM1/p62 mutations 
associated with PDB and overexpression of native p62, are 
increasing osteoclast responsiveness to RANK ligand76,104,105 
and osteoclast survival,76 which translates clinically into a 
more severe phenotypic expression of the disease.67
Treatment
indications for therapy
Guidelines on clinical management of PDB have been pub-
lished by expert committees from various countries.10,32,107–109 
Pain in pagetic bone is the only symptom of PDB for which 
there is firm evidence that therapy confers a clinical benefit,110 
and is, therefore, a definite indication for antipagetic therapy. 
It is important to distinguish bone pain that occurs as a result 
of pagetic activity (ie, pain in pagetic bone) from pain in a 
bone and/or joint deformity that occurs as a consequence of 
the disease (ie, osteoarthritic pain). The former is usually 
present at rest, whereas the latter occurs during mobilization 
of the joint and can, therefore, respond to analgesics, but not 
to antipagetic drugs.
Pharmacological treatment to prevent future compli-
cations, such as osteoarthritis, fracture, hearing loss, or 
other neurological complications, is more controversial.111 
In a 12-year study of 41 patients with PDB, osteoarthritic 
complications occurred in 62% of patients, in whom serum 
total alkaline phosphatase levels were halved after therapy 
compared with 33% of those who had normal serum total 
alkaline phosphatase following treatment.112 Therefore, 
a reasonable strategy is to treat pain even when its cause 
is unclear, because it can often be difficult to distinguish 
between PDB pain and osteoarthritic pain.10 Both symptom-
atic and asymptomatic patients with metabolically active 
PDB requiring therapy include those with involvement of 
long bones at risk of future bowing deformities, those with 
extensive skull involvement at risk for future hearing loss, 
those with pagetic changes in one or more vertebrae with 
the risk of various neurological complications, and those 
with PDB in bones adjacent to major joints with the risk of 
secondary arthritis.32,107 Because current therapies improve 
radiographic osteolytic lesions113 and allow normal lamellar 
bone deposition,114 it is likely that associated complications 
could be prevented if treatment is administered at an early 
stage.111,112,115 A recent three-year prospective study known 
as PRISM (Paget’s Disease: a Randomized Trial of Intensive 
Versus Symptomatic Management)116 in 1324 patients with 
long established PDB, concluded that intensive bisphospho-
nate therapy has no beneficial effect on quality of life, bone 
pain, or clinical complications (fracture and osteoarthritis) 
compared with symptomatic management. The negative 
  findings from the PRISM trial could be explained by numer-
ous limitations in the trial design.115,117 Unevenly potent 
treatment was given late in the disease process, the primary 
endpoint was inadequate (ideally pain or alternatively frac-
ture in pagetic bone should have been used rather than clinical 
fracture at any site), and the sample size was too small and 
the observational period too short to impact on the clinical 
management of PDB. For preventing complications associ-
ated with PDB, initiating pharmacological therapy at the right 
time (at an early disease stage) is clearly more important than 
using a highly potent bisphosphonate.
Contraindications to therapy
Elderly asymptomatic patients whose life span would likely 
limit the chance of future complications111 and those with 
metabolically inactive pagetic lesions (no radiographic oste-
olytic lesions nor increased uptake on bone scintigraphy) are 
not candidates for pharmacological therapy. Patients with 
vitamin D deficiency should be repleted before therapy is 
initiated to prevent severe hypocalcemia.118
Goals of therapy
Physicians treating PDB should aim for a complete remission, 
as defined by normalization of serum total alkaline phos-
phatase and even a nadir value in the lower half of the refer-
ence range.119 The ideal therapeutic option would eliminate 
bone pain, normalize serum total alkaline phosphatase with 
prolonged remission, heal radiographic osteolytic lesions, 
restore normal lamellar bone, and prevent recurrence and 
complications.32
Current pharmacological therapies
The first effective therapy was salmon calcitonin, available 
in the 1970s as daily subcutaneous formulations, followed 
by human calcitonin. Calcitonin acts directly on calcitonin 
receptors expressed on osteoclasts.120 Because calcitonin was 
associated with partial response, acquired resistance, and 
a short-lived action, it is not used clinically any more.
Bisphosphonates are a class of drugs related to the 
naturally occurring mineralization inhibitor, inorganic 
pyrophosphate.121 In biological systems, they are able to 
bind to the surface of hydroxyapatite crystals within bone, 
especially on those surfaces undergoing active osteoclastic 
  resorption.   Bisphosphonates work according to one of two 
main mechanisms of action, depending on the chemical nature 
of the side chain attached to the basic bisphosphonate core. 
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(ie, etidronate, clodronate, and tiludronate) inhibit bone 
resorption by generating a toxic analog of adenosine triphos-
phate, which then targets the mitochondria.122 For the more 
potent, nitrogen-containing bisphosphonates (ie, alendronate, 
ibandronate, pamidronate, risedronate, and zoledronic 
acid), the direct intracellular target in osteoclasts is the 
farnesyl pyrophosphate synthase enzyme in the mevalonate 
  pathway.122 Its inhibition suppresses a process called protein 
prenylation, which is essential for the basic cellular processes 
required for osteoclastic bone resorption and cell survival.
Nitrogen-containing bisphosphonates are the treatment of 
choice for PDB. The advent of ever more powerful bispho-
sphonates has led to an aim for a more stringent definition 
of biochemical response to therapy, ie, a reduction of serum 
total alkaline phosphatase into the normal range and even a 
nadir value in the lower half of the reference range.119
Comparative trials have been published evaluating the 
relative efficacy of the bisphosphonates in the treatment 
of PDB. These trials typically use extent of suppression of 
serum total alkaline phosphatase and duration of remission as 
evidence of superior treatment. Table 1 provides a summary 
of the clinical trials assessing the efficacy of bisphosphonates 
in PDB, as measured by the proportion of patients achieving 
normalization of serum total alkaline phosphatase.42,123–128 
This table reports the results from independent studies with-
out any attempt to compare efficacy between therapies that 
have not been compared in a head-to-head trial. Although 
of somewhat differing protocols, these trials demonstrate 
that alendronate and risedronate are superior to etidronate. 
In a small comparative study of previously untreated patients, 
oral alendronate (40 mg/day in three-month blocks) and 
intravenous pamidronate (60 mg every three months) were 
given until normalization of serum total alkaline phos-
phatase, which was observed at one year in 86% and 56% 
of patients, respectively.129 In previously treated patients, 
alendronate resulted in normalization of serum total alkaline 
  phosphatase in 79% compared with 14% for pamidronate.129 
At one year, nonresponders to pamidronate were crossed over 
to alendronate treatment, and 71% achieved normalization 
of serum total alkaline phosphatase.129 In another compara-
tive trial, normalization of serum total alkaline phosphatase 
was achieved at six months in 93% of patients treated with 
intravenous zoledronic acid 4 mg and in 35% of patients 
treated with intravenous pamidronate 60 mg every three 
months.130 At six months, nonresponders to pamidronate 
were treated with intravenous zoledronic acid 4 mg or 
intravenous neridronate 100 mg, and normalization of serum 
total alkaline phosphatase was achieved in more than 90%.130 
A once-weekly alendronate 280 mg oral buffered solution 
was recently compared with an alendronate 40 mg/day tablet. 
While both were similarly effective (percentage of patients 
with serum total alkaline phosphatase normalization not 
provided), the 40 mg daily tablet was better tolerated.131 
Recent comparison of intravenous zoledronic acid 5 mg and 
oral risedronate 30 mg daily for 60 days in 357 patients after 
six months showed normalization of serum total alkaline 
phosphatase in 89% of zoledronic acid-treated patients and 
58% of risedronate-treated patients.128
In the zoledronic acid group, mean scores for each of 
the eight components of the SF-36 trended upward at both 
three and six months, suggesting improvements in quality 
of life, whereas the responses were more mixed in the rise-
dronate group.128 Patients in remission at six months were 
followed for duration of response and, after two years,132 
zoledronic acid 5 mg extended remission in 98% of 
patients with one single dose, compared with 57% with 
risedronate, and at 5–6 years these figures were 87% and 
38%,   respectively.133 Acquired resistance has been com-
monly observed with etidronate and pamidronate, but not 
with alendronate, risedronate, or zoledronic acid.134 Upper 
gastrointestinal intolerance and abdominal pain have been 
reported as the most frequent adverse events associated with 
oral bisphosphonates.135 Postinfusion syndrome (a flu-like 
illness) occurs in about 15% of patients treated with intra-
venous bisphosphonates (pamidronate, ibandronate, and 
zoledronic acid), and this almost exclusively at the first 
infusion.119,128 Oral bisphosphonates should not be used 
in patients with esophageal stricture or dysmotility. All 
bisphosphonates should be avoided in patients with renal 
insufficiency and severe vitamin D deficiency. Osteonecrosis 
of the jaw and subtrochanteric fractures are very rare events 
and their pathophysiology remains unclear.135 However, 
overall, only a very small proportion of patients treated with 
Table  1  Summary  of  clinical  trials  assessing  bisphosphonate 
efficacy in Paget’s disease of bone as measured by the proportion of 
patients with normalization of serum total alkaline phosphatase
Drug name Regimen Duration % n sTALP
etidronate123 400 mg/day, oral 6 months 15
*Clodronate124 1600 mg/day, oral 6 months 60
*Tiludronate125 400 mg/day, oral 3 months 39
*Pamidronate126 60 mg/day, iv 3 days 53
*Alendronate127 40 mg/day, oral 6 months 63
Risedronate123 30 mg/day, oral 2 months 73
*ibandronate42 6 mg/day, iv 2 days 70
Zoledronic acid128 5 mg, iv One dose 89
Note: *Small sample size.
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  bisphosphonates experience adverse events and the overall 
benefits have consistently outweighed their potential risks.
Monitoring and retreatment
Serum total alkaline phosphatase is the most commonly used 
method of monitoring disease activity.10 It should be mea-
sured every three months for the first six months after therapy 
and every six months thereafter.10 Pretherapeutic serum total 
alkaline phosphatase is often within the normal range in 
monostotic disease, and it cannot be used for monitoring.136 
Bone scintigraphy (normal uptake) or plain radiographs 
(filling of osteolytic lesions113) performed six months after 
treatment would constitute the ideal monitoring. Retreatment 
is usually indicated when there are persistent symptoms of 
PDB or biochemical relapse.10 Although there is no clinical 
trial evidence to guide clinicians, it is generally accepted that 
an increase of 25% above nadir indicates significant relapse 
requiring retreatment.10
Mechanisms of action  
of bisphosphonates in PDB
Recent in vitro studies suggest that pulse treatment with 
zoledronic acid, achieving micromolar concentrations (rather 
than the nanomolar concentrations usually observed in clini-
cal use) similar to what is observed with a single intravenous 
infusion of 5 mg, causes inhibition of proliferation and 
induction of apoptosis in human mesenchymal stem cells and 
enhances differentiation through the osteoblastic lineage.137 
Emerging preclinical and clinical evidence suggests that, in 
addition to their selected inhibition of osteoclastic activity, 
bisphosphonates exert anticancer activity by interacting with 
monocytes, macrophages, and tumor cells, and by stimulating 
the expansion of γδ T cells, a subset of human T cells with 
antitumor activity.138 Focal high bone turnover lesions like 
PDB or bone metastases do enrich bisphosphonates in the 
surrounding bone. Only under those circumstances may 
it be envisaged that bisphosphonate concentrations in the 
microenvironment exceed micromolar concentrations for 
a longer period of time and thus propagate apoptosis of 
pluripotential hematopoietic progenitors, leading to the long-
term remissions observed in PDB after a single intravenous 
zoledronic acid infusion.133
Potential therapeutic targets
Although bisphosphonates are currently the treatment of 
choice for the management of PDB, uncertainty about the 
long-term health consequences of these drugs may now lead 
to consideration of potential alternative therapies, particularly 
targeted therapies already designed and used, or about to be 
used, in clinical practice for the management of other bone 
disorders.
RANK ligand inhibition
RANK ligand inhibition by the use of a fully human mono-
clonal antibody (denosumab) induces, in clinical trials, 
a profound but reversible inhibition of bone resorption. 
This targeted therapy may be considered for the treatment 
of OPG/RANK/RANK ligand pathway-mediated diseases, 
mainly postmenopausal osteoporosis, bone erosion in 
inflammatory arthritis, and cancer-induced bone disease.139 
In PDB, the OPG/RANK/RANK ligand system is usually 
normal, although enhanced RANK ligand expression and 
responsivity in bone marrow cells have been reported.98 
Moreover, the pathophysiology of several PDB-related dis-
eases involves the OPG/RANK/RANK ligand system, such 
as mutation in the signal peptide region of the RANK gene 
in familial expansile osteolysis and a mutation in the OPG 
gene in juvenile Paget’s disease.140
interleukin-6 inhibition
Almost 20 years ago, osteotropic factors, such as 1,25(OH)2 
vitamin D3, parathyroid hormone, and IL-1, were shown to 
stimulate osteoblast release of IL-6 which, at low concen-
trations (,10 ng/mL), stimulates osteoclast formation from 
precursors, and at higher concentrations, stimulates mature 
osteoclasts to resorb bone.141 IL-6 plays a central role in the 
development of the abnormal phenotype of osteoclast in 
PDB, mainly in the multinucleation and hypersensitivity to 
1,25(OH)2 vitamin D3.90 IL-6 was found to be overexpressed 
in pagetic osteoblasts, and may be involved in both stimula-
tion of osteoclast proliferation and inhibition of osteoblast 
growth.2 However, a recent study did not find any association 
of common polymorphisms in IL-6, IL-8, and tumor necrosis 
factor alpha genes with PDB.142 Tocilizumab, an IL-6 recep-
tor inhibitor, has recently been approved for the treatment 
of rheumatoid arthritis.143 Although IL-6 plays a key role in 
causing joint damage in rheumatoid arthritis through possible 
indirect effects on osteoclastogenesis and bone resorption,144 
no clinical trials have been initiated to date in metabolic bone 
disorders associated with high levels of IL-6.
Dickkopf-1 inhibition
Dickkopf-1 is a natural secreted antagonist of the Wnt/ 
β-catenin signaling interacting with the LRP5/6 coreceptor 
(Figure 1). Surprisingly, Dickkopf-1 RNA and protein 
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giving new insights into the role of the osteoblast in PDB. 
A later independent study reported increased circulating 
Dickkopf-1 levels in serum from PDB patients,145 and sug-
gested Dickkopf-1 as a potential therapeutic target in PDB.146 
Indeed, high levels of Dickkopf-1 have also been reported in 
multiple myeloma, osteosarcoma, and rheumatoid arthritis, 
and Dickkopf-1 targeted therapy gave preliminary promising 
results in multiple myeloma and rheumatoid arthritis.146
Strategies for novel therapeutic 
target identification
Relevant strategies for the identification of novel therapeutic 
targets in PDB may rely mostly on the investigation of novel 
targets developed for the management of other bone disorders 
and of the results from genetic studies.
investigation of novels targets  
developed in other bone disorders
Several metabolic disorders share common pathophysiologi-
cal features with PDB, such as multiple myeloma, osteopo-
rosis, rheumatoid arthritis-induced bone erosions, and bone 
metastases of cancer with high affinity for bone, such as 
prostate and breast cancers. In both PDB and bone metastases, 
increased osteoclast formation and the increased osteoclasto-
genic nature of the bone microenvironment are mediated by 
common factors, namely IL-6 and RANK ligand.147 Available 
data suggest that, in the case of PDB, there is increased RANK 
ligand and IL-6 production, and IL-6 enhances responsivity 
of the osteoclast precursors to RANK ligand, contributing to 
the elevated numbers of osteoclasts. In patients with multiple 
myeloma, 95%–100% of whom develop osteolytic bone 
lesions, both IL-6 and RANK ligand levels are increased.147 
We will mainly focus the remaining discussion on therapeutic 
targets for multiple myeloma and osteoporosis
Bone destruction in multiple myeloma is associated 
with increased osteoclast formation and activity like in 
PDB, but with decreased or absent osteoblast differentia-
tion and activity.148 The impairment of osteoblast activity 
in multiple myeloma results primarily from blockade of 
osteogenic differentiation of mesenchymal progenitors 
into mature   osteoblasts. Multiple myeloma patients have 
low to normal levels of bone formation markers, such as 
alkaline phosphatase and osteocalcin, in the setting of 
increased bone resorption. In contrast, multiple myeloma 
patients without bone lesions display balanced bone remod-
eling with increased osteoclastogenesis and normal or 
increased bone formation rates. Both soluble factors and 
cell-to-cell contact between multiple myeloma cells and 
osteoblast progenitors are responsible for the suppression 
of osteoblast differentiation in multiple myeloma. Current 
approaches for the development of target-specific treatment 
in multiple myeloma concern mainly second-generation 
proteasome inhibitors, new immunomodulating drugs or 
thalidomide derivatives, histone deacetylase, and heat shock 
protein 90 inhibitors.149–151
Other potential targets are represented by inhibitors 
of Akt and of PI3K/Akt signaling (rapamycin inhibitors), 
Bcl2 inhibitors and other promoters of apoptotic   pathways, 
MAPK and telomerase inhibitors, to name a few.151 
  Antibodies have also been designed in multiple myeloma 
to inhibit IL-6, CD56 (neuronal cell adhesion molecule), 
CD138 (syndecan-1, a receptor for endothelial growth factor 
ligands) and Cs1, a cell surface glycoprotein.151 In addition 
to bisphosphonates, novel therapies are considered for the 
treatment of bone disease in multiple myeloma, such as 
denosumab, which specifically inhibits RANK ligand-RANK 
interaction, bortezomib which is a proteasome antagonist 
inducing myeloma cell apoptosis, and   immunomodulating 
drugs, which inhibit osteoclast activity by decreasing the 
expression of cathepsin K.152 Other inhibitors targeting 
natural antagonists of Wnt signaling, such as Dickkopf-1 
and secreted frizzled-related proteins, have been targeted, 
as well as inhibitors of IL-3 and Il-7.152
Osteoporosis is characterized by a generalized increase 
in bone resorption, whereas PDB has both focal excesses of 
bone resorption and many unaffected bones that preserve 
normal bone remodeling. Both antiresorptive and anabolic 
agents have being designed as potential novel therapies 
in osteoporosis. In addition to denosumab, another antire-
sorptive agent called odanacatib, which is an inhibitor of 
cathepsin K, is currently being investigated in osteoporosis, 
as well as glucagon-like peptide 2, an intestinal hormone 
which may act as an antiresorptive agent with no reduction 
in bone formation.153 Novel anabolic agents targeting the Wnt 
signaling pathway designed for future osteoporosis manage-
ment should be considered with caution, and may probably 
be contraindicated in PDB, considering the increased risk of 
osteosarcoma in this disorder.
Results of genetic studies
Gene expression profiling in RNA extracted from various 
cell types in pagetic patients has revealed that a huge num-
ber of genes may be significantly upregulated or downregu-
lated in PDB, providing novel insights for potential future 
targeted therapies (Table 2).2,154,155 Considering difficulties 
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genome-wide analyses, such as the genome-wide associa-
tion study recently published in PDB,55 or genome-wide 
investigations of copy number alterations or epigenetic 
modifications, may be considered as innovative and prom-
ising ways to identify novel targets or novel pathways for 
potential future therapies in PDB. Indeed, the recently 
published genome-wide association study reported a strong 
genetic association with three common polymorphisms 
located upstream of the CSF1 gene.55 CSF1 gene encodes 
macrophage colony-stimulating factor, which is a key 
cytokine secreted by bone marrow stromal cells and osteo-
blasts, which induces the expression of RANK in osteoclast 
precursors, further inducing osteoclast differentiation and 
osteoclast activity and survival regulation.156 Serum levels 
of macrophage colony-stimulating factor were reported to 
be significantly increased in PDB patients who were not 
currently treated, suggesting that serum measurement of 
macrophage colony-stimulating factor may be an indica-
tor of disease activity.157 Although CS1 antibody, antisense 
oligonucleotide, and CSF1 small interfering RNA strate-
gies have demonstrated tumor suppression capabilities in 
several disease (excluding PDB) and model systems,158,159 
it is not yet clear enough how specific is their intervention 
on osteoclast formation, in bone disorders such as PDB, 
because other cell lineages derived from hematopoetic 
precursors use similar signaling pathways.160
Table 2 Genes which showed statistically significant differential gene expression in various cell types from patients affected by Paget’s 
disease of bone
Gene symbol Encoded protein Human cell type Reference
Downregulated genes
ACP5 Acid phosphatase 5, tartrate resistant Osteoclast* 154
CASP3 Caspase 3, apoptosis-related cysteine peptidase Osteoclast* 154
CTSK Cathepsin K Osteoclast* 154
FLJ23191 Chromosome 4 open reading frame 31 Osteoblast 2
GCA Grancalcin, eF-hand calcium binding protein Osteoblast 2
GLRB Glycine receptor, beta Osteoblast 2
MAFB V-maf musculoaponeurotic fibrosarcoma 
oncogene homolog B (avian)
Osteoblast 2
MAPT Microtubule-associated protein tau Osteoclast* 154
SATB2 SATB homeobox 2 Osteoblast 2
TNFα Tumor necrosis factor Monocytes 
Lymphocytes
155
TNFRSF10A Tumor necrosis factor receptor superfamily, 
member 10a
Osteoclast* 154
TNFRSF11A Tumor necrosis factor receptor superfamily, 
member 11a, NFKB activator
Osteoclast* 154
Upregulated genes
EPB41L4B erythrocyte membrane protein band 4.1 like 4B Osteoblast 2
GULP1 GULP, engulfment adaptor PTB domain containing 1 Osteoblast 2
IFNα interferon, alpha 1 Monocytes 
Lymphocytes
155
IFNβ Interferon, beta 1, fibroblast Monocytes 
Lymphocytes
155
IFNγ interferon, gamma Monocytes 
Lymphocytes
155
IFNγ-R1 interferon gamma receptor 1 Monocytes 
Lymphocytes
155
IFNγ-R2 interferon gamma receptor 2 
(interferon gamma transducer 1)
Monocytes 
Lymphocytes
155
KRT18 Keratin 18 Osteoblast 2
P38 β2 MAPK Mitogen-activated protein kinase 14 Monocytes 155
RAI3 G protein-coupled receptor, family C, 
group 5, member A
Osteoblast 2
RBPMS RNA binding protein with multiple splicing Osteoblast 2
STAT1 Signal transducer and activator of transcription 1, 91 kDa Monocytes 155
STAT2 Signal transducer and activator of transcription 2, 113 kDa Lymphocytes 155
TNXB Tenascin XB Osteoblast 2
Note: *Peripheral blood monocytes differentiated in vitro into mature osteoclasts.Drug Design, Development and Therapy 2011:5 submit your manuscript | www.dovepress.com
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Conclusion
In conclusion, nitrogen-containing bisphosphonates are cur-
rently the treatment of choice for PDB, particularly with the 
last generation and more powerful bisphosphonates, which 
have led us to aim for a more stringent definition of biochemi-
cal response to therapy. Major advances in the understanding 
of PDB pathophysiology in recent years could give rise to 
novel alternative treatment, such as targeted therapies, as a 
medium-term perspective for the management of PDB and 
other bone metabolic disorders.
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